Consensus Emergent BioSolutions Inc.

Stocks

EBS

US29089Q1058

Pharmaceuticals

Market Closed - NYSE 16:00:02 2026-10-30 EDT			5-day change	1st Jan Change
6.810 ^USD	-5.68%		+9.31%	-44.90%

10-16	Emergent BioSolutions Inc. Announces Chief Financial Officer Changes	CI
10-16	Emergent BioSolutions Inc. Announces Executive Changes	CI

Evolution of the Average Target: Emergent BioSolutions Inc.

Evolution of the Target Price: Emergent BioSolutions Inc.

Changes in Analyst Recommendations: Emergent BioSolutions Inc.

1ca51d34d7fc708b4082fd94.9-TAVox5qSFnlthUQZgpM2f-tCUPE_dSv4bsIFuYWPw.kpOuHN8b7WJUxustOc1YVgLP7FF7UbA_3MChEG3bO8-vvaIjzQ_dQyDQnQ~9509e208975a22bc9636fee44bc40963

Analysts' recommendations: Emergent BioSolutions Inc.

24-12-30	Emergent BioSolutions Shares Rise After HC Wainwright Begins Coverage With Buy Rating	MT
24-12-30	HC Wainwright Initiates Emergent BioSolutions at Buy With $15 Price Target	MT
24-06-20	Benchmark Adjusts Emergent Biosolutions Price Target to $8 From $5, Maintains Buy Rating	MT
24-03-07	Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5	MT
23-08-29	Benchmark Downngrades Emergent Biosolutions to Hold From Buy	MT
23-04-10	Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $22	MT
23-03-17	JPMorgan Downgrades Emergent Biosolutions to Underweight From Neutral, Adjusts Price Target to $9 From $23	MT
22-11-09	Chardan Cuts Price Target on Emergent Biosolutions to $55 From $65 on Slower Revenue, Profitability Growth; Keeps Buy Rating	MT
22-09-12	Cowen Trims Emergent Biosolutions Price Target to $29 From $30, Maintains Market Perform Rating	MT
22-05-04	Wells Fargo Adjusts Emergent Biosolutions' Price Target to $38 from $46, Keeps Equalweight Rating	MT
22-05-02	Cantor Fitzgerald Cuts Emergent Biosolutions to Neutral From Overweight, Price Target to $33 From $55	MT
22-03-10	JPMorgan Trims Price Target for Emergent Biosolutions to $57 From $58, Maintains Neutral Rating	MT
22-03-10	Wells Fargo Adjusts Emergent Biosolutions' Price Target to $40 from $37, Keeps Equalweight Rating	MT
22-01-20	Benchmark Upgrades Emergent Biosolutions to Buy from Hold, Sets $77 Price Target	MT
22-01-20	Cantor Fitzgerald Adjusts Price Target on Emergent Biosolutions to $55 From $50, Reiterates Overweight Rating	MT
21-11-10	Chardan Adjusts Price Target on Emergent Biosolutions to $75 From $92, Maintains Buy Rating	MT
21-11-08	Benchmark Capital Downgrades Emergent Biosolutions to Hold From Buy	MT
21-05-05	Emergent BioSolutions : Argus Research Downgrades Emergent Biosolutions to Hold From Buy	MT
21-04-30	Emergent BioSolutions : Chardan Adjusts Price Target on Emergent Biosolutions to $92 From $112, Maintains Buy Rating	MT
21-04-30	Emergent BioSolutions : Benchmark Adjusts Price Target on Emergent Biosolutions to $120 From $150, Maintains Buy Rating	MT
21-04-14	Emergent BioSolutions : Guggenheim Adjusts Price Target on Emergent Biosolutions to $110 From $130, Maintains Buy Rating	MT
21-04-07	Emergent BioSolutions : Benchmark Starts Emergent Biosolutions at Buy with $150 Price Target	MT
21-02-24	Emergent BioSolutions : Chardan Upgrades Emergent BioSolutions to Buy From Neutral, Maintains $112 Price Target	MT
21-02-19	Emergent BioSolutions : Chardan Downgrades Emergent Biosolutions to Neutral Rating From Buy; Price Target is $112	MT
21-01-08	Emergent BioSolutions : Wells Fargo Downgrades Emergent Biosolutions to Equalweight from Overweight, Keeps $110 Price Target	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EMERGENT BIOSOLUTIONS INC.					+61.53%
	ELI LILLY AND COMPANY					-1.45%
	JOHNSON & JOHNSON					+2.27%
	ABBVIE INC.					-3.97%
	ROCHE HOLDING AG					-2.72%
	MERCK & CO., INC.					+7%
	NOVARTIS AG					-5.37%
	ASTRAZENECA PLC					+12.5%
	AMGEN INC.					-14.74%
	GILEAD SCIENCES, INC.					-3.15%
	Average					+5.19%
	Weighted average by Cap.					-0.77%